Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.
Mondello P, Paludo J, Novak JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Dasari S, Manske MK, Abeykoon JA, Sarangi V, Kapoor P, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan AA, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Mondello P, et al. Among authors: reeder cb. Clin Cancer Res. 2023 Mar 1;29(5):957-970. doi: 10.1158/1078-0432.CCR-22-2215. Clin Cancer Res. 2023. PMID: 36534518
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Lacy MQ, et al. Among authors: reeder cb. Mayo Clin Proc. 2006 Aug;81(8):1047-53. doi: 10.4065/81.8.1047. Mayo Clin Proc. 2006. PMID: 16901028 Review.
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. Stewart AK, et al. Among authors: reeder cb. Leukemia. 2007 Mar;21(3):529-34. doi: 10.1038/sj.leu.2404516. Epub 2007 Jan 18. Leukemia. 2007. PMID: 17230230
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Dispenzieri A, et al. Among authors: reeder cb. Mayo Clin Proc. 2007 Mar;82(3):323-41. doi: 10.4065/82.3.323. Mayo Clin Proc. 2007. PMID: 17352369
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Kapoor P, et al. Among authors: reeder cb. Blood. 2009 Jul 16;114(3):518-21. doi: 10.1182/blood-2009-01-202010. Epub 2009 Mar 26. Blood. 2009. PMID: 19324902 Free PMC article.
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Kumar SK, et al. Among authors: reeder cb. Mayo Clin Proc. 2009 Dec;84(12):1095-110. doi: 10.4065/mcp.2009.0603. Mayo Clin Proc. 2009. PMID: 19955246 Free PMC article.
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Gay F, et al. Among authors: reeder cb. Blood. 2010 Feb 18;115(7):1343-50. doi: 10.1182/blood-2009-08-239046. Epub 2009 Dec 11. Blood. 2010. PMID: 20008302 Free PMC article.
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE. Ghobrial IM, et al. J Clin Oncol. 2010 Mar 10;28(8):1408-14. doi: 10.1200/JCO.2009.24.0994. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142598 Free PMC article. Clinical Trial.
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. Johnston PB, et al. Among authors: reeder cb. Am J Hematol. 2010 May;85(5):320-4. doi: 10.1002/ajh.21664. Am J Hematol. 2010. PMID: 20229590 Free PMC article. Clinical Trial.
106 results